金水宝胶囊联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的疗效观察

Observation on Efficacy of Jinshuibao Capsules Combined with Budesonide and Formoterol Fumarate Powder for Inhalation in Treatment of Bronchial Asthma

目的:探讨金水宝胶囊联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的临床疗效及安全性。方法:选取2015年2月—2016年8月山东省邹平县中心医院收治的支气管哮喘患者92例作为研究对象,以随机数字表法分为观察组和对照组,每组46例。对照组患者给予基础对症治疗和布地奈德福莫特罗粉吸入剂治疗,观察组患者在对照组的基础上加用金水宝胶囊治疗,两组患者均持续治疗1个月。观察2组患者的临床疗效、肺功能及血气指标水平、不良反应发生情况。结果:治疗前,两组患者哮喘控制测试表评分的差异无统计学意义(P>0.05);治疗后,观察组患者哮喘控制测试表评分为(20.18±2.03)分,明显低于对照组的(23.74±1.95)分,差异有统计学意义(P<0.05)。治疗后,观察组患者1 s用力呼气容积、1 s用力呼气容积占用力肺活量百分比、呼吸峰流速、动脉血氧分压水平明显高于对照组,差异均有统计意义(P<0.05)。观察组患者不良反应发生率为8.70%(4/46),明显低于对照组的26.09%(12/46),差异有统计学意义(P<0.05)。结论:金水宝胶囊联合布地奈德福莫特罗粉吸入剂治疗支气管哮喘的疗效显著,可有效改善患者肺功能和血气指标,不良反应较少。

To probe into the clinical efficacy and safety of Jinshuibao capsules combined with budesonide and formoterol fumarate powder for inhalation. METHODS： 92 patients with bronchial asthma admitted into Shandong Zouping County Central Hospital from Feb. 2015 to Aug. 2016 were selected to be divided into observation group and control group via the random number table, with 46 cases in each. The control group were given symptomatic treatment and budesonide and formoterol fumarate powder for inhalation; while the control group were treated with Jinshuibao capsules based on the control group. The treatment course was 1 month. The clinical efficacy, lung function and blood gas index level and adverse reactions were observed in two group of patients. RESULTS： Before treatment, there was no significant difference in ACT score between two groups before （P 〉 0. 05）. After treatment, the ACT score in observation group was （20. 18 ± 2. 03 ） scores, significantly lower than that of the control group [ （23.74 ± 1.95 ） scores], with statistically significant difference（P 〈0.05）. After treatment, the FEV1, FEV/FVC, PEF, PaO2 of observation group was higher than that of control group, with statistically significant difference （P 〈 0. 05 ）. The incidence of adverse drug reactions of observation group was 8.70% （4/46）, significantly lower than that of control group [ 26. 09% （12/46） ], with statistically significant difference （ P 〈 0. 05 ）. CONCLUSIONS ： The efficacy of Jinshuibao capsules combined with budesonide and formoterol fumarate powder for inhalation is remarkable, which can improve patients＇ lung function and blood gas indexes with few adverse drug reactions.